543 results
REC-CAGEFREE II, NOTION-2, LANDMARK: Three major late-breaking trials presented at EuroPCR 2024
15 May 2024
The Course Directors have selected 3 major Late Breaking Trials (LBTs) that were presented for the first time during the 2024 edition of EuroPCR. These trials were selected on account of their design, outcomes and potential to influence daily clinical practice.
An image is worth a 1,000 words
15 May 2024 – From EuroPCR 2024
Make your life easier with imaging during primary PCI for acute coronary syndrome
15 May 2024 – From EuroPCR 2024
This session features selected EuroPCR 2024 Clinical Case submissions highlighting the use of imaging modalities, such as optical coherence tomography (OCT) and intravascular ultrasound (IVUS), during primary percutaneous coronary interventions (PCI) for acute coronary syndrome. Experts will present and discuss challenging cases, demonstrating how the integration...
DCB PCI for de novo lesions: when and how?
15 May 2024 – From EuroPCR 2024
In this session, you will learn how to optimally perform DCB PCI, identify which lesions are best suited for this approach, and understand when it's necessary to switch from DCB to stent PCI. The session also features a debate on whether DCB-PCI should be the first...
Major Late-Breaking Trials from EuroPCR 2024
15 May 2024 – From EuroPCR 2024
This session presents the latest results from major late-breaking trials presented at EuroPCR 2024. It covers a one-month DAPT followed by 5-month ticagrelor monotherapy in acute coronary syndromes with DCB, the first TAVI vs. SAVR randomised trial in younger low-risk patients with severe tricuspid or bicuspid...
Stentless PCI
15 May 2024 – From EuroPCR 2024
This session explores various stentless percutaneous coronary intervention (PCI) strategies, including drug-coated balloon (DCB)-only PCI for chronic total occlusions and de-novo coronary lesions, as well as the use of magnesium resorbable scaffolds. Attendees will learn about the rationale, techniques, and outcomes of these "leave nothing behind"...
Artificial intelligence-powered quantification of coronary physiology and vulnerable plaque: opportunities for novel treatment options
15 May 2024 – From EuroPCR 2024
In this session, uncover new data on Murray-law based quantitative flow ratio (muFR) assessment, providing a comprehensive understanding of PCI outcomes from a single angiographic view, explore the innovative application of artificial intelligence in identifying vulnerable plaque and assessing hemodynamic stenosis significance through the analysis of...
Second generation biolimus drug-coated balloon in clinical practice
15 May 2024 – From EuroPCR 2024
Discover the potential applications of the new biolimus-coated balloon in treating de novo large vessel lesions, explore its effectiveness in addressing ISR based on findings from the BIO ASCEND ISR study, and uncover insights into the safety and feasibility of BA9 DCB in treating small vessel,...
Go beyond metal: exploring drug-eluting balloon technology in de-novo coronary lesions
15 May 2024 – From EuroPCR 2024
Through the study of two cases, this session examines the need for stenting bifurcation lesions and the role of DEB technology in avoiding stent-related complications in long diffuse disease. It emphasizes the benefits of SELUTION SLR balloons for de novo lesions, discussing how sustained limus release...
PCI complications: device-related issues, perforations and other unexpected events
15 May 2024 – From EuroPCR 2024
This session focuses on the management of various complications that can occur during percutaneous coronary intervention (PCI), including device-related issues, perforations, and other unexpected events. Attendees will learn from case presentations and discussions on strategies to identify, mitigate, and manage these complications, with a focus on...
